DMT vs Ketamine
A side-by-side research comparison of DMT and Ketamine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | DMT | Ketamine |
|---|---|---|
| Full name | N,N-Dimethyltryptamine | Ketamine (and esketamine) |
| Category | Psychedelics | Psychedelics |
| Status | Schedule I (research compound) | Schedule III; esketamine FDA-approved for depression |
| Mechanism | Activates serotonin 5-HT2A receptors, producing vivid changes in perception. When taken orally in ayahuasca, an MAO inhibitor is needed so it is not broken down too quickly. | Blocks NMDA glutamate receptors, which is thought to quickly boost synaptic connections and lift mood. This is a different pathway from classic serotonin psychedelics. |
| Molecular weight | 188.27 g/mol | 237.73 g/mol |
| Half-life | ~10-15 minutes | ~2-3 hours |
| Bioavailability | Inhaled/injected (very short); oral only with an MAO inhibitor | IV, intramuscular, nasal, oral (varies) |
| Typical dose | Controlled dosing in clinical studies | Low sub-anesthetic doses for depression (clinic-administered) |
| Frequency | One to a few supervised sessions | A series of supervised sessions |
| Route | Inhalation or IV in research; oral as ayahuasca | IV infusion, intramuscular, or nasal spray (esketamine) |
DMT reported benefits
- Studied for depression
- Very short experience aids research design
- Used to study consciousness
- Long traditional use as ayahuasca
Ketamine reported benefits
- Rapid relief from treatment-resistant depression
- FDA-approved option (esketamine) exists
- Can reduce suicidal thoughts quickly
- Useful when other antidepressants fail
Related comparisons
Research and educational reference only. Not medical advice.